论文部分内容阅读
目的：研究HBVDNA浓度与临床疾病关系及对干扰素治疗效果进行评价。方法：应用竞争性聚合酶链反应技术检测42例慢性乙型肝炎（慢乙肝）患者血清HBVDNA含量，并对26例患者进行了人白细胞干扰素治疗前后循环血中HBVDNA浓度的动态观察。结果:慢乙肝患者血清HBVDNA含量在5×100～5×108拷贝μl之间；血清HBVDNA含量与ALT活性相关关系不明显（r=0.2862，P＞0．05）；干扰素治疗前完全反应组HBVDNA浓度显著低于部分反应组（t=4.84，P＜0.01）和无反应组（t=6．26，P＜0．01）。结论：HBV感染后产生的各种临床疾病类型可能主要归于宿生免疫应答的不同，HBVDNA浓度较低的患者（小于10000拷贝／μl）干扰素治疗效果较好，定量检测HBVDNA浓度在抗病毒药物疗效预测和评价中是一个有重要意义的参考指标。
Objective: To study the relationship between HBVDNA concentration and clinical disease and to evaluate the effect of interferon treatment. Methods: The serum HBVDNA levels in 42 patients with chronic hepatitis B (CHB) were detected by competitive polymerase chain reaction (PCR). The dynamic changes of HBVDNA in circulating blood before and after human leukocyte interferon (IFN) treatment were evaluated in 26 patients. Results: Serum HBVDNA levels in patients with chronic hepatitis B were between 5 × 100 and 5 × 108 copies μl. There was no significant correlation between serum HBVDNA content and ALT activity (r = 0.2862, P> 0.05). Pretreatment with complete response group The HBVDNA concentration was significantly lower than that of the partial reaction group (t = 4.84, P <0.01) and no reaction group (t = 6.26, P <0.01). CONCLUSIONS: The types of clinical diseases that may develop after HBV infection may be mainly attributed to different immune responses. Interferon treatment with less HBVDNA (less than 10 000 copies / μl) is more effective in detecting HBVDNA levels in anti-viral drugs The efficacy prediction and evaluation is a significant reference index.